SIC
CLVS

SJS Investment Consulting’s Clovis Oncology, Inc. CLVS Stock Holding History

SJS Investment Consulting’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1K Hold
500
– – ﹤0.01% 653
2021
Q4 		$1K Buy
+500
New +$1.85K ﹤0.01% 520

Other funds holding CLVS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

SJS Investment Consulting's CLVS Position: Q1 2022 in Review

SJS Investment Consulting held its Clovis Oncology, Inc. (CLVS) position steady in Q1 2022 at 500 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #653.

SJS Investment Consulting first reported a position in CLVS in Q4 2021 and has held it in 2 quarters since. 153 funds tracked by Wall St. Rank hold CLVS as of Q1 2022.

  • SJS Investment Consulting held 500 shares of Clovis Oncology, Inc. worth $1K as of Q1 2022.
  • SJS Investment Consulting left its Clovis Oncology, Inc. share count unchanged in Q1 2022.
  • Clovis Oncology, Inc. made up ﹤0.01% of SJS Investment Consulting's portfolio in Q1 2022, its #653 holding.
  • SJS Investment Consulting first reported a position in Clovis Oncology, Inc. in Q4 2021 and has held it in 2 quarters since.
  • 153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2022.

Based on SJS Investment Consulting's 13F filing for Q1 2022, filed 5 May 2022.